We are grateful to work with Arc and 10x Genomics to advance the development of these resources to accelerate scientific discovery and advance our understanding of biology’s complexity." ...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.

Arc Institute continues its work to generate and share large-scale, high-quality datasets of cell state before and after chemical or genetic perturbations to enable "virtual cell" models and other ...

Shares of TXG opened at $7.14 on Tuesday. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $37.74. The stock’s fifty day moving average price is $10.96 and its two-hundred day moving ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers. The ...

TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools ...

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers. The life ...

Dear Customers, Researchers and Friends of Vizgen: On February 5th, we secured an important settlement putting an end to litigation, including cases in the U.S. and Europe, with 10X Genomics and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...